Loading...

Minerva Neurosciences

Nasdaq:NERV
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NERV
Nasdaq
$255M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
  • Minerva Neurosciences has significant price volatility in the past 3 months.
NERV Share Price and Events
7 Day Returns
-1.7%
NasdaqGM:NERV
-1.9%
US Biotechs
0.6%
US Market
1 Year Returns
-20.2%
NasdaqGM:NERV
-11.9%
US Biotechs
4.1%
US Market
NERV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Minerva Neurosciences (NERV) -1.7% 49.7% -7% -20.2% -38.5% -0.3%
US Biotechs -1.9% 1.7% 0.8% -11.9% 9.7% 7.8%
US Market 0.6% 3.8% 2.8% 4.1% 37.3% 42.5%
1 Year Return vs Industry and Market
  • NERV underperformed the Biotechs industry which returned -11.9% over the past year.
  • NERV underperformed the Market in United States of America which returned 4.1% over the past year.
Price Volatility
NERV
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Minerva Neurosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Minerva Neurosciences. This is due to cash flow or dividend data being unavailable. The share price is $6.54.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Minerva Neurosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Minerva Neurosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:NERV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.38
NasdaqGM:NERV Share Price ** NasdaqGM (2019-07-17) in USD $6.54
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.51x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Minerva Neurosciences.

NasdaqGM:NERV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:NERV Share Price ÷ EPS (both in USD)

= 6.54 ÷ -1.38

-4.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Minerva Neurosciences is loss making, we can't compare its value to the US Biotechs industry average.
  • Minerva Neurosciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Minerva Neurosciences's expected growth come at a high price?
Raw Data
NasdaqGM:NERV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.74x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
52.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.81x
United States of America Market PEG Ratio Median Figure of 2,122 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Minerva Neurosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Minerva Neurosciences's assets?
Raw Data
NasdaqGM:NERV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.98
NasdaqGM:NERV Share Price * NasdaqGM (2019-07-17) in USD $6.54
United States of America Biotechs Industry PB Ratio Median Figure of 436 Publicly-Listed Biotechs Companies 3.03x
United States of America Market PB Ratio Median Figure of 5,241 Publicly-Listed Companies 1.81x
NasdaqGM:NERV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:NERV Share Price ÷ Book Value per Share (both in USD)

= 6.54 ÷ 1.98

3.3x

* Primary Listing of Minerva Neurosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Minerva Neurosciences is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Minerva Neurosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Minerva Neurosciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Minerva Neurosciences expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Minerva Neurosciences expected to grow at an attractive rate?
  • Minerva Neurosciences's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Minerva Neurosciences's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Minerva Neurosciences's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:NERV Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:NERV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 52.4%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:NERV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:NERV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 477 249 147 2
2022-12-31 259 -11 -8 2
2021-12-31 53 -95 -90 2
2020-12-31 0 -117 -99 3
2019-12-31 0 -59 -68 3
NasdaqGM:NERV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -41 -54
2018-12-31 -42 -50
2018-09-30 -41 -37
2018-06-30 -6 -36
2018-03-31 -2 -33
2017-12-31 3 -32
2017-09-30 3 -41
2017-06-30 -26 -38
2017-03-31 -26 -34
2016-12-31 -26 -31
2016-09-30 -23 -30
2016-06-30 -24 -28

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Minerva Neurosciences's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Minerva Neurosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:NERV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Minerva Neurosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NERV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.94 5.65 0.22 2.00
2022-12-31 -0.17 0.53 -0.86 2.00
2021-12-31 -2.09 -1.95 -2.23 2.00
2020-12-31 -2.31 -1.62 -3.31 3.00
2019-12-31 -1.69 -1.62 -1.79 3.00
NasdaqGM:NERV Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.38
2018-12-31 -1.29
2018-09-30 -0.95
2018-06-30 -0.92
2018-03-31 -0.86
2017-12-31 -0.83
2017-09-30 -1.11
2017-06-30 -1.08
2017-03-31 -1.00
2016-12-31 -0.99
2016-09-30 -1.04
2016-06-30 -1.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Minerva Neurosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Minerva Neurosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Minerva Neurosciences has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Minerva Neurosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Minerva Neurosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Minerva Neurosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Minerva Neurosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Minerva Neurosciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Minerva Neurosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Minerva Neurosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NERV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -53.58 17.25 38.05
2018-12-31 -50.17 16.84 34.89
2018-09-30 -36.81 15.21 32.42
2018-06-30 -36.05 13.61 33.01
2018-03-31 -33.30 12.34 31.09
2017-12-31 -31.52 10.91 30.26
2017-09-30 -41.09 10.66 30.21
2017-06-30 -38.25 10.59 27.11
2017-03-31 -33.69 10.24 22.68
2016-12-31 -31.05 9.75 20.44
2016-09-30 -30.08 8.95 20.20
2016-06-30 -27.60 8.44 18.18
2016-03-31 -28.99 8.04 19.95
2015-12-31 -27.08 7.58 18.53
2015-09-30 -26.08 10.12 15.24
2015-06-30 -47.30 10.59 36.21
2015-03-31 -60.06 11.84 46.28
2014-12-31 -56.90 11.96 42.91
2014-09-30 -51.59 9.35 40.10
2014-06-30 -24.92 7.29 15.50
2014-03-31 -5.93 4.32 1.19
2013-12-31 -3.26 2.45 0.71
2013-09-30 -1.43 0.77 0.66
2012-12-31 -1.58 1.03 0.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Minerva Neurosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Minerva Neurosciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Minerva Neurosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Minerva Neurosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Minerva Neurosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Minerva Neurosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Minerva Neurosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Minerva Neurosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Minerva Neurosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Minerva Neurosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Minerva Neurosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Minerva Neurosciences Company Filings, last reported 3 months ago.

NasdaqGM:NERV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 77.42 0.00 79.16
2018-12-31 90.26 0.00 88.00
2018-09-30 101.39 0.00 97.61
2018-06-30 110.66 1.40 108.49
2018-03-31 121.29 2.70 121.00
2017-12-31 131.60 3.96 128.16
2017-09-30 130.18 5.19 132.93
2017-06-30 98.03 6.39 77.57
2017-03-31 106.29 7.56 85.36
2016-12-31 105.98 8.69 82.98
2016-09-30 113.14 9.80 91.85
2016-06-30 120.61 10.10 97.06
2016-03-31 66.65 10.02 44.64
2015-12-31 55.32 9.94 32.20
2015-09-30 63.07 9.86 37.49
2015-06-30 68.38 9.78 35.39
2015-03-31 74.44 9.71 52.20
2014-12-31 51.50 0.00 18.55
2014-09-30 56.72 0.00 23.64
2014-06-30 29.23 3.39 0.48
2014-03-31 34.09 0.83 2.14
2013-12-31 20.18 0.06 1.82
2013-09-30 0.73 0.00 1.10
2012-12-31 0.02 0.00 0.20
  • Minerva Neurosciences has no debt.
  • Minerva Neurosciences has no debt compared to 5 years ago when it was 2.5%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Minerva Neurosciences has sufficient cash runway for 1.9 years based on current free cash flow.
  • Minerva Neurosciences has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 11.3% each year.
X
Financial health checks
We assess Minerva Neurosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Minerva Neurosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Minerva Neurosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Minerva Neurosciences dividends. Estimated to be 0% next year.
If you bought $2,000 of Minerva Neurosciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Minerva Neurosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Minerva Neurosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:NERV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 18 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:NERV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Minerva Neurosciences has not reported any payouts.
  • Unable to verify if Minerva Neurosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Minerva Neurosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Minerva Neurosciences has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Minerva Neurosciences's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Minerva Neurosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Minerva Neurosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Minerva Neurosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Minerva Neurosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rémy Luthringer
COMPENSATION $3,910,245
AGE 58
TENURE AS CEO 4.7 years
CEO Bio

Dr. Rémy Luthringer, Ph.D., has been Executive Chairman of Minerva Neurosciences, Inc. since February 2018. Dr. Luthringer has been the Chief Executive Officer of Minerva Neurosciences, Inc. since November 2014 and served as its President from November 2014 to December 2017. Mr. Luthringer serves as Advisor at Index Ventures. He joined Index Ventures in 2010 and established the Geneva office. Dr. Luthringer serves as an Advisor at Medicxi Ventures. He serves as the Chief Medical Officer at the Index Life VI biotech fund raised by Index Ventures in 2012. He served as the Chief Scientific Officer at Minerva Neurosciences, Inc. He served as an Executive Vice President and Head of Research & Development at Minerva Neurosciences Inc. since March 2014. He has provided consulting services to Minerva Neurosciences since January 2011. He served as the Chief Medical Officer and Partner at Index Ventures since December 2010. He served as the Chief Executive Officer at Groupe FORENAP and FORENAP Pharma EURL. He served as the Chief Executive Officer and President at the FORENAP Institute for Research in Neurosciences and Neuropsychiatry from 2005 to September of 2010. He served as the Chief Executive Officer at one of the research institutes in neurosciences. He had advisory roles in several companies including the following: Funxional Therapeutics, Linguaflex and V-Watch. He has been a Director of Minerva Neurosciences, Inc. since November 2014. He serves as a Member of Scientific Advisory Board at Index Life VI. He has been a Member of the Scientific Advisory Board of Somnus Therapeutics, Inc. since November 2008. He was involved in several European grants and research programs focusing on development and validation of biomarkers or surrogate endpoints. He served on advisory boards of biotech as well as pharmaceutical companies and was involved in the development of more than 150 CNS active molecules and has carried out more than 700 clinical trials. He spent some years in clinical psychiatric practice. He focuses on investments in life sciences, healthcare infrastructure in Switzerland, France and United Kingdom. Dr. Luthringer received a Ph.D. in Neurosciences and in Clinical Pharmacology from University Louis Pasteur, France. He received a Masters Degree in Functional Explorations and Computer Engineering from University Paris VI, France and a obtained a Nursing Degree in Psychiatry from Rouffach Hosptial, France.

CEO Compensation
  • Rémy's compensation has increased whilst company is loss making.
  • Rémy's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Minerva Neurosciences management team in years:

4.3
Average Tenure
58
Average Age
  • The tenure for the Minerva Neurosciences management team is about average.
Management Team

Rémy Luthringer

TITLE
Executive Chairman & CEO
COMPENSATION
$4M
AGE
58
TENURE
4.7 yrs

Rick Russell

TITLE
President
COMPENSATION
$2M
AGE
55
TENURE
1.6 yrs

Geoff Race

TITLE
Executive VP
COMPENSATION
$2M
AGE
58
TENURE
5.2 yrs

Devin Smith

TITLE
Senior VP
COMPENSATION
$2M
AGE
51
TENURE
1 yrs

Joe Reilly

TITLE
Senior VP & COO
COMPENSATION
$1M
AGE
44
TENURE
5 yrs

Fred Ahlholm

TITLE
Senior VP & Chief Accounting Officer
COMPENSATION
$845K
AGE
53
TENURE
5 yrs

William Boni

TITLE
Vice President of Investor Relations & Corporate Communications
AGE
67
TENURE
3.9 yrs

Michael Davidson

TITLE
Chief Medical Officer
COMPENSATION
$3M
AGE
69
TENURE
2.6 yrs

Jay Saoud

TITLE
Senior VP and Head of Research & Development
AGE
60
Board of Directors Tenure

Average tenure and age of the Minerva Neurosciences board of directors in years:

1.6
Average Tenure
61
Average Age
  • The average tenure for the Minerva Neurosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jan van Heek

TITLE
Independent Director
COMPENSATION
$157K
AGE
70
TENURE
5 yrs

Rémy Luthringer

TITLE
Executive Chairman & CEO
COMPENSATION
$4M
AGE
58
TENURE
1.4 yrs

Fouzia Laghrissi-Thode

TITLE
Director
COMPENSATION
$153K
AGE
56
TENURE
4.2 yrs

David Kupfer

TITLE
Director
COMPENSATION
$150K
AGE
78
TENURE
3.7 yrs

Bill Doyle

TITLE
Lead Independent Director
COMPENSATION
$273K
AGE
57
TENURE
1.4 yrs

Hans Hasler

TITLE
Director
COMPENSATION
$153K
AGE
63
TENURE
1.6 yrs

Jeri Hilleman

TITLE
Independent Director
COMPENSATION
$241K
AGE
61
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Minerva Neurosciences individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. Jul 19 Buy William Doyle Individual 27. Jun 19 27. Jun 19 3,500 $5.50 $19,250
27. Jun 19 Buy G. van Heek Individual 26. Jun 19 26. Jun 19 10,000 $5.37 $53,700
27. Jun 19 Buy Jeryl Hilleman Individual 26. Jun 19 26. Jun 19 1,000 $5.25 $5,250
27. Jun 19 Buy Hans Hasler Individual 26. Jun 19 26. Jun 19 10,000 $5.60 $56,000
27. Jun 19 Buy David Kupfer Individual 26. Jun 19 26. Jun 19 10,000 $5.55 $55,500
26. Jun 19 Sell Index Ventures Company 24. Jun 19 24. Jun 19 -194,000 $6.01 $-1,166,794
21. Jun 19 Sell Index Ventures Company 19. Jun 19 20. Jun 19 -110,818 $4.44 $-488,911
19. Jun 19 Sell Index Ventures Company 17. Jun 19 18. Jun 19 -105,918 $4.45 $-470,730
18. Jun 19 Sell Index Ventures Company 17. Jun 19 17. Jun 19 -56,243 $4.45 $-250,208
17. Jun 19 Sell Index Ventures Company 13. Jun 19 13. Jun 19 -78,179 $4.51 $-352,442
13. Jun 19 Sell Index Ventures Company 11. Jun 19 12. Jun 19 -60,051 $4.78 $-281,343
21. May 19 Sell Index Ventures Company 17. May 19 20. May 19 -22,918 $6.08 $-137,896
16. May 19 Sell Index Ventures Company 14. May 19 16. May 19 -134,828 $7.05 $-898,161
26. Dec 18 Buy William Doyle Individual 20. Dec 18 20. Dec 18 2,000 $6.50 $13,000
13. Dec 18 Sell Richard Russell Individual 12. Dec 18 12. Dec 18 -3,117 $7.96 $-24,811
12. Dec 18 Buy William Doyle Individual 10. Dec 18 11. Dec 18 6,000 $8.00 $47,800
21. Nov 18 Buy William Doyle Individual 20. Nov 18 20. Nov 18 2,000 $8.20 $16,400
15. Oct 18 Buy William Doyle Individual 11. Oct 18 11. Oct 18 600 $10.00 $6,000
03. Oct 18 Sell Index Ventures Company 01. Oct 18 01. Oct 18 -15,444 $12.35 $-190,747
01. Oct 18 Sell Index Ventures Company 27. Sep 18 28. Sep 18 -66,273 $12.62 $-834,618
19. Sep 18 Buy William Doyle Individual 17. Sep 18 17. Sep 18 1,800 $10.50 $18,900
17. Sep 18 Buy William Doyle Individual 13. Sep 18 14. Sep 18 2,200 $10.50 $23,100
11. Sep 18 Buy William Doyle Individual 10. Sep 18 11. Sep 18 8,011 $9.88 $78,507
X
Management checks
We assess Minerva Neurosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Minerva Neurosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?

With a market capitalization of US$217m, Minerva Neurosciences is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Minerva Neurosciences NasdaqGM:NERV Ownership Summary, June 26th 2019 What Does The Institutional Ownership Tell Us About Minerva Neurosciences? … As you can see, institutional investors own 75% of Minerva Neurosciences.

Simply Wall St -

Introducing Minerva Neurosciences (NASDAQ:NERV), The Stock That Slid 56% In The Last Three Years

The more recent news is of little comfort, with the share price down 39% in a year. … See our latest analysis for Minerva Neurosciences With zero revenue generated over twelve months, we don't think that Minerva Neurosciences has proved its business plan yet. … A Different Perspective Over the last year, Minerva Neurosciences shareholders took a loss of 39%.

Simply Wall St -

Does The Minerva Neurosciences, Inc. (NASDAQ:NERV) Share Price Tend To Follow The Market?

In finance, Beta is a measure of volatility. … Volatility is considered to be a measure of risk in modern finance theory. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).

Simply Wall St -

What Type Of Shareholder Owns Minerva Neurosciences, Inc.'s (NASDAQ:NERV)?

Every investor in Minerva Neurosciences, Inc. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … With a market capitalization of US$327m, Minerva Neurosciences is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Read This Before Selling Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares

So we'll take a look at whether insiders have been buying or selling shares in Minerva Neurosciences, Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Minerva Neurosciences Insider Transactions Over The Last Year.

Simply Wall St -

Before You Buy Minerva Neurosciences Inc (NASDAQ:NERV), Consider Its Volatility

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Simply Wall St -

What Type Of Shareholder Owns Minerva Neurosciences Inc's (NASDAQ:NERV)?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Minerva Neurosciences is a smaller company with a market capitalization of US$411m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Does Minerva Neurosciences Inc (NASDAQ:NERV) Go Up With The Market?

The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … Not every stock is exposed to the same level of market risk.

Simply Wall St -

Minerva Neurosciences Inc's (NASDAQ:NERV) Profit Outlook

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. … The company’s loss has recently broadened since it announced a -US$31.52m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$33.30m, moving it further away from breakeven … Many investors are wondering the rate at which NERV will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

Minerva Neurosciences Inc (NERV): Risks You Need To Consider Before Buying

See our latest analysis for NERV An interpretation of NERV's beta Minerva Neurosciences has a beta of 1.57, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts. … A high level of beta means investors face higher risk associated with potential gains and losses driven by market movements. … NERV, with its market capitalisation of USD $201.24M, is a small-cap stock, which generally have higher beta than similar companies of larger size.

Simply Wall St -

Company Info

Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company’s lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company’ preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, NV for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Details
Name: Minerva Neurosciences, Inc.
NERV
Exchange: NasdaqGM
Founded: 2007
$255,226,580
39,025,471
Website: http://www.minervaneurosciences.com
Address: Minerva Neurosciences, Inc.
1601 Trapelo Road,
Suite 286,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM NERV Common Stock Nasdaq Global Market US USD 01. Jul 2014
DB 4MN Common Stock Deutsche Boerse AG DE EUR 01. Jul 2014
Number of employees
Current staff
Staff numbers
13
Minerva Neurosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 00:43
End of day share price update: 2019/07/17 00:00
Last estimates confirmation: 2019/06/25
Last earnings filing: 2019/05/06
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.